Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures
May 28, 2019Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure
Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …
FDA delays Newron Pharmaceuticals’ trial into schizophrenia drug evenamide
May 28, 2019Manufacturing and Production Newron Pharma, evenamide, pharma, schizophrenia
Newron Pharmaceuticals has halted a clinical trial of its schizophrenia drug evenamide after the FDA raised concerns about reports of …
Pharma sector is a bigger polluter than the automotive industry
May 28, 2019Manufacturing and Production CO2, Green, eco-firendly, emissions, pharma, pollution
The pharmaceutical industry is a bigger polluter than the automotive sector, according to a study from researchers at McMaster University. …
FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer
May 28, 2019Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma
Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …
Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy
May 28, 2019Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma
The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …
FDA approves new tests for chlamydia and gonorrhoea
May 24, 2019Medical Communications STIs, chlamydia, gonorrhoea, public health FDA
The FDA has approved two new tests which make it easier to diagnose common STIs. The approval comes after a …
Top Ten most popular articles on Pharmafile.com this week
May 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten
On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …
China approves GSK’s shingles vaccine Shingrix
May 24, 2019Medical Communications, Sales and Marketing China, GSK, Shingrix, pharma, shingles
GSK’s shingles vaccine has secured approval in China, the company said, after the National Medical Products Administration (NMPA) authorised the …
Mumps cases triple in England
May 24, 2019Medical Communications MMR, UK, Vaccine, health, public health
Public Health England has urged patients to ensure that they have received the MMR vaccine after the number of cases …
GSK to reintroduce bonuses for sales reps
May 24, 2019Medical Communications GSK, US, oncology, pharma, sales, sales reps, scandal
British multinational GlaxoSmithKline said on Thursday that it would reintroduce performance-based bonuses for some sales reps in some countries. The …
Drugmakers colluded to drive up price of anti-nausea drug by 700%
May 23, 2019Business Services, Medical Communications Business, NHS, collusion, competition, pharma
Four pharmaceutical firms have been accused of illegally colluding to restrict the supply of anti-nausea medication Prochlorperazine after the price …
Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression
May 23, 2019Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression
Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …
Japan’s health ministry warns of serious side effects of Lilly’s Verzenio
May 23, 2019Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma
Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …
KCL study could lead to improved vaccinations against STIs
May 23, 2019Research and Development HIV, HSV, STIs, herpes, immune system, std
New findings from researchers at King’s College London could lead to improved vaccinations against sexually transmitted infections (STIs). Researchers at …
Akcea’s Tegsedi secures NICE approval for Stage 1 or 2 polyneuropathy in hATTR
May 23, 2019Sales and Marketing Akcea Therapeutics, NHS, NICE, Tegsedi, UK, pharma
Akcea Therapeutics’ Tegsedi (inotersen) has received recommendation from NICE, the company has revealed, meaning the therapy will now be made …
Array Biopharma’s Braftovi triple therapy meets both endpoints in advanced colorectal cancer subtype
May 22, 2019Research and Development Array Biopharma, Braftovi, Cancer, colorectal cancer, pharma
Array Biopharma has revealed new data on its combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), showing that it …
Amgen agrees to buy Nuevolution for $167 million
May 22, 2019Research and Development Amgen, Cancer, Nuevolution, biotech, drug discovery, immuno-oncology, immunology, pharma
California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million). The …
Takeda scores Japanese Entyvio approval in Crohn’s disease
May 22, 2019Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma
Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …
MSD buys Peloton Therapeutics in deal worth $2.1 billion
May 22, 2019Research and Development Cancer, MSD, acquisition, biotech, deal, oncology, pharma
MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion. US …
Children wait six and half years longer than adults for new cancer drugs, study says
May 22, 2019Research and Development Cancer, FDA, children, oncology, paediatrics, pharma
Children wait six and half years longer than adults to access new cancer drugs, according to a study from Dana-Farber/Boston …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
